Abstract
The field of endoscopy has progressed markedly and become widespread in recent years, and the role of minimally invasive endoscopic treatment has become increasingly more important with the increase in the number of patients in whom gastric cancer is detected at an early stage. In addition, the characteristics of early gastric cancer, which can be curably treated by mucosal resection alone just as by surgical cancer resection, were clarified, and endoscopic submucosal dissection (ESD) was developed as a highly curable, minimally invasive treatment, that is gaining popularity. In this paper, we describe the technical details and complications of ESD for early gastric cancer, including their management.
Highlights
The characteristics of early gastric cancer, which can be curably treated by mucosal resection alone just as by surgical cancer resection, were clarified, and endoscopic submucosal dissection (ESD) was developed as a highly curable, minimally invasive treatment, that is gaining popularity
We describe the technical details and complications of ESD for early gastric cancer, including their management
More than 20 years have passed since the introduction of endoscopic mucosal resection (EMR) to the treatment of digestive tract tumors, and endoscopic treatment is widely performed for early digestive tract cancers including stomach as well as esophageal and colon cancers [1,2,3,4]
Summary
More than 20 years have passed since the introduction of endoscopic mucosal resection (EMR) to the treatment of digestive tract tumors, and endoscopic treatment is widely performed for early digestive tract cancers including stomach as well as esophageal and colon cancers [1,2,3,4]. Endoscopic submucosal dissection (ESD) was reported as treatment for early-stage gastric cancer in the late 1990s in Japan, and it has rapidly spread, surpassing conventional endoscopic mucosal resection (EMR) [5,6,7]. We describe the indications of endoscopic treatment for early gastric cancer (EGC), technical details of ESD, diagnosis of the tumor extent during treatment, complications, and their management
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have